
Please try another search
On Mar 25, we issued an updated research report on Integra LifeSciences Holdings Corporation (NASDAQ:IART) . The company has been noticing certain major developments overseas. However, a tough competitive landscape is a concern. The stock currently carries a Zacks Rank #2 (Buy).
This New Jersey-based company is a leading developer, manufacturer and marketer of surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics and general surgery.
In fourth-quarter 2019, the company registered balanced segmental growth. The Codman Specialty Surgical segment grew 4.1%, while Orthopedics and Tissue Technologies revenues inched up 1.3%. The impressive quarterly performance of DuraGen in Japan, following the third-quarter launch, instills optimism.
During the December-end quarter, revenues from the Codman Specialty Surgical segment climbed 5.6%, organically aided by the completion of all integration activities related to the Codman acquisition, scale expansion, product launches, and venturing into faster-growing markets like China and Japan.
We are currently upbeat about the longer-term revenue contributions from the Arkis Biosciences and Rebound Therapeutics acquisitions. Expansion of both margins also contributed to the share-price rally.
Meanwhile, softer sales in outpatient settings and the impact of supply constraints in the reported quarter are concerning. The company faces stiff competition in the surgical implants and medical instruments market. It needs continued innovation to deflect rivalry. Moreover, consolidations in the industry might induce an intense pricing pressure.
Also, the worldwide supply disruption and economic stagnation amid the coronavirus outbreak has caused share-price depreciation.Integra has underperformed its industry in the past three months. The stock has lost 33.6% compared with the industry’s 24.5% loss.
Key Picks
Some better-ranked stocks in the broader medical space are ResMed Inc. (NYSE:RMD) , Medtronic plc (NYSE:MDT) and Hill-Rom Holdings, Inc (NYSE:HRC) .
ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic’s long-term earnings growth rate is estimated at 7.4%. The company presently holds a Zacks Rank of 2.
Hill-Rom’s long-term earnings growth rate is projected at 11.1%. It currently carries a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Home Depot’s (NYSE:HD) Q4 2024 report and guidance for 2025 have plenty to be unhappy about, but the simple truth is that this company turned a corner in 2024. It is on track for...
Nvidia is scheduled to release its Q4 earnings report at 4:20PM ET on Wednesday. A call with CEO Jensen Huang is set for 5:00PM ET. The chipmaker’s results will serve as a...
Warren Buffett has always critiqued airline stocks for being overly capital-intensive, exhibiting low growth, and relying heavily on cyclical consumer travel patterns—further...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.